Pediatric systemic lupus erythematosus: more than a positive antinuclear antibody

Area of Science:

• Rheumatology
• Pediatric Autoimmunity

Background:

• Pediatric Systemic Lupus Erythematosus (pSLE) is a complex autoimmune disease.
• Understanding pSLE's unique clinical presentation and risk factors is crucial for early diagnosis and management.

Purpose of the Study:

• To summarize key diagnostic features, disease burden, and risk factors associated with pSLE.
• To highlight treatment considerations for lupus nephritis and associated complications.

Main Methods:

• Review of strong research evidence and expert consensus on pSLE diagnosis and management.
• Analysis of factors contributing to disease burden and complications such as thrombosis and atherosclerosis.

Main Results:

• Common pSLE manifestations include constitutional symptoms, arthritis, and malar rash.
• pSLE patients show significant organ involvement but low mortality.
• Antinuclear Antibody (ANA) is typically positive (≥1:160) in SLE.
• Mycophenolate mofetil (MMF) and cyclophosphamide are effective for lupus nephritis induction.
• Antiphospholipid antibodies increase venous thrombosis risk.
• Subclinical atherosclerosis risk is elevated in pSLE with specific risk factors.

Conclusions:

• pSLE diagnosis relies on characteristic symptoms and positive ANA.
• Effective treatments exist for lupus nephritis, but vigilance for thrombosis and atherosclerosis is necessary.
• Despite disease burden, pSLE outcomes are generally favorable with appropriate management.